These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16408098)

  • 1. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
    Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
    Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
    Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
    Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
    Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
    Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
    Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
    Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
    Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 15. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
    Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A
    Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Jones AV; Kreil S; Zoi K; Waghorn K; Curtis C; Zhang L; Score J; Seear R; Chase AJ; Grand FH; White H; Zoi C; Loukopoulos D; Terpos E; Vervessou EC; Schultheis B; Emig M; Ernst T; Lengfelder E; Hehlmann R; Hochhaus A; Oscier D; Silver RT; Reiter A; Cross NC
    Blood; 2005 Sep; 106(6):2162-8. PubMed ID: 15920007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
    Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
    Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
    Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
    Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.